Age-related Eye Diseases: An Emerging Challenge for Public Health Professionals by Maylahn, Christopher et al.
VOLUME 2: NO. 3 JULY 2005
Age-related Eye Diseases: An Emerging
Challenge for Public Health Professionals
MINIREVIEW
Suggested citation for this article: Gohdes DM,
Balamurugan A, Larsen BA, Maylahn C. Age-related eye
diseases: an emerging challenge for public health profes-
sionals. Prev Chronic Dis [serial online] 2005 Jul [date




In April 2004, The Eye Disease Prevalence Research
Group published a series of articles that included age-
specific estimates for the prevalence of low vision and
blindness in whites, African Americans, and Hispanics
living in the United States. Also included were age-,
sex-, and ethnic-specific incidences of the following
age-related eye diseases: diabetic retinopathy, macu-
lar degeneration, cataracts, and glaucoma.
We reviewed the group’s series of articles and high-
lighted key findings on the overall prevalence of and risk
factors for age-related eye diseases, as well as opportuni-
ties to preserve and restore vision. We examined publica-
tions that show the public health impact of age-related
eye diseases and the importance of projected increases in
prevalence of low vision and blindness.
Approximately 1 in 28 Americans aged older than 40
years is affected by low vision or blindness. Among com-
munity-dwelling adults, the prevalence of low vision and
blindness increases dramatically with age in all racial and
ethnic groups. Whites have higher rates of macular degen-
eration than African Americans, but glaucoma is more
common among older African Americans. Between 2000
and 2020, the prevalence of blindness is expected to double.
Age-related eye diseases are costly to treat, threaten the
ability of older adults to live independently, and increase
the risk for accidents and falls. To prevent vision loss and
support rehabilitative services for people with low vision,
it is imperative for the public health community to address
the issue through surveillance, public education, and coor-
dination of screening, examination, and treatment.
Introduction
Age-related eye diseases (AREDs) that lead to low vision
and blindness are a growing challenge for public health
professionals (1). New estimates for the prevalence of
AREDs and vision loss became available in 2004 from The
Eye Disease Prevalence Research Group and showed that
1 in 28 Americans aged older than 40 years is blind or has
low vision (2,3). Although treatments exist to prevent or
delay vision loss for several of these conditions, the num-
ber of blind individuals is expected to double by 2020 as
the U.S. population ages (2,3). In this review, we summa-
rize the age, sex, and race prevalence rates for each of four
AREDs — diabetic retinopathy, macular degeneration,
cataracts, and glaucoma — and describe risk factors for
the diseases. We also discuss the impact of AREDs and
opportunities to prevent blindness, restore vision, and sup-
port people with visual impairments.
Prevalence and Risk Factors for Age-related
Eye Diseases
Diabetic retinopathy
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Of the AREDs, diabetic retinopathy is most familiar to
public health professionals because of the efforts of state
diabetes programs to increase eye examination rates
among people with diabetes. Vision loss from diabetic
retinopathy can result from several diabetes-related
changes in the eye, but early recognition and treatment
(including laser therapy) can prevent blindness (4,5).
Treatment recommendations emphasize the need for
aggressive blood glucose and blood pressure control to
reduce the incidence, progression, and severity of diabetic
retinopathy (6). Although a few studies have found a rela-
tionship between smoking and the risk of diabetic retinopa-
thy progression, the conclusion of the most recent Surgeon
General’s report on the health consequences of smoking
was that the evidence did not support a causal relationship
between smoking and diabetic retinopathy (7).
In the United States, some form of diabetic retinopathy
was detected in 40% of people with diabetes (8). Vision-
threatening retinopathy was much less common, develop-
ing in 8% of people with diabetes. Because retinopathy
depends on the duration of hyperglycemia rather than age,
the actual prevalence of retinopathy among people with
diabetes did not increase markedly when stratified by age
(9). However, the prevalence of retinopathy in the general
U.S. population older than 40 years was 3.4% and
increased with age, reflecting the higher rates of diabetes
in older persons (8).
Age-related macular degeneration
Like diabetic retinopathy, age-related macular degenera-
tion (AMD) has several forms (10,11). The form known as
wet AMD is caused by abnormal vascularization under the
retina and is an important cause of central vision loss. Dry
AMD, the most common form, tends to progress more slow-
ly than the wet form. The most advanced form, geographic
atrophy, also causes central vision loss. Although the
pathogenesis of AMD is not totally understood, 54% of the
cases of blindness in white Americans have been attributed
to the disease (2). AMD increases dramatically with age in
men and women, but no significant sex difference in rates
has been found (12). AMD is less common in African
Americans than in whites. According to community eye
studies, as many as 16% of white women and 12% of white
men aged 80 years and older have advanced AMD.
Several pathophysiological processes associated with
aging have been proposed as etiologies for AMD, and
research on the topic continues (13). In one study, high-
dose supplements of vitamins C and E, beta carotene, and
zinc slowed the rate of progressive vision loss somewhat
over 5 years, but only when the condition was not extreme-
ly advanced (14). The recognition of a link between high-
dose supplements of beta carotene in smokers and
increased cardiovascular risk may have discouraged eye-
care professionals and patients from using the vitamin-
supplement regimen found to be effective (15,16).
However, it has been estimated that in 300,000 people
aged 55 years and older, additional vision loss over the
next 5 years can be prevented if the supplementation
study results are translated into widespread clinical prac-
tice (17). Laser therapy and photodynamic therapy can be
used successfully for some forms of wet AMD, although the
disease is particularly complex and challenging to treat
(10,11). New forms of therapy, such as injecting antivas-
cular endothelial growth factor, effectively reduced the
progression of vision loss in a randomized trial of people
with advanced wet AMD (18,19). No surgical interventions
for the dry form of the disease exist, although the efficacy
of laser photocoagulation of the macula to prevent pro-
gression of early disease is being studied. Rehabilitative
interventions for individuals who are in their 80s and 90s
and have low vision because of AMD are challenging, but
quality of life can be improved (20). Helping the growing
number of older adults with low vision to function inde-
pendently will tax the already strained vision rehabilita-
tion resources in many communities.
Cataracts
Cataracts are the most common ARED. In community
studies, more than 17% of Americans aged 40 and older
were estimated to have one or more cataracts, and 5%
reported having had surgery to remove a cataract from one
or both eyes (21). In 1991, 1.35 million surgical procedures
to remove cataracts were performed among Medicare ben-
eficiaries at an estimated cost of $3.4 billion (22).
Cataracts were the cause of about 50% of cases of vision
loss in white, African American, and Hispanic people (2).
Women were somewhat more likely to be affected than
men (21), but African American men were more likely to
be blind from cataracts than white men (2). Variations in
access to surgical treatment may account for some of the
disparities. In east Baltimore, Md, blindness resulting
from a cataract that had received no surgical treatment
was four times more prevalent in African Americans than
whites (23). In addition, the types of cataracts found most
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Because the lens naturally becomes more opaque over
time, aging is the most important risk factor for develop-
ing cataracts. Although smoking has been implicated as a
risk factor for developing nuclear cataracts, the conclusion
of the Surgeon General’s report on the health conse-
quences of smoking is that the evidence is insufficient to
conclude that smoking cessation reduces the risk for devel-
oping cataracts (7). Some studies revealed that a family
history of cataracts and certain iris colors were risk fac-
tors, as were hypertension and diabetes (25). Increased
exposure to sunlight, particularly ultraviolet B radiation,
is also associated with an increased risk for developing
cataracts (26). Surgical cataract removals are common,
although local variations in surgical practice exist (22).
Glaucoma
The incidence of glaucoma also increases with age. Risk
factors other than age include a family history of glauco-
ma, African American ancestry, and diabetes (27). No sig-
nificant sex differences were found in community studies
(28). Vision loss in people with glaucoma is caused by a
progressive loss of optic nerve fibers (27). Elevated intraoc-
ular pressure (IOP) is an important factor associated with
loss of visual function, but not all patients with progressive
vision loss from glaucoma experience consistently elevated
pressure. Evaluating IOP is an important part of an eye
examination when screening for glaucoma, but the diag-
nosis is based on detecting changes in the optic nerve and
retinal nerve fibers during examination and by demon-
strating decreased visual function, particularly in the
periphery, using visual field testing. Most individuals with
elevated IOP do not have optic nerve damage or changes
in their visual fields, but studies have found that 1 in every
15 Americans with elevated IOP (higher than 21 mm Hg)
has optic nerve changes typical of glaucoma (27).
Treatments to decrease vision loss from the various patho-
physiological processes that cause glaucoma have been
well tested in numerous clinical trials (27). Because reduc-
ing elevated IOP is the mainstay of treatment to prevent
vision loss, it is important to identify those with undiag-
nosed glaucoma before irreversible damage has occurred.
In people aged 40 and older in the United States, the
prevalence of glaucoma revealed by examination was
1.86%; the rate for African Americans was three times
that for whites (28). However, these estimates do not
include the numbers of people with elevated IOP (3).
People with elevated IOP need careful treatment and fol-
low-up examinations to prevent the development of irre-
versible vision loss (27).
Impact of Age-related Eye Diseases on
Public Health
The new prevalence estimates of AREDs, vision loss, and
blindness in the United States have several important pub-
lic health implications (2,3). First, a person often has more
than one ARED, so aging individuals are at risk for multi-
ple eye problems. Second, although The Eye Disease
Prevalence Research Group studies demonstrated impor-
tant disparities between African Americans and whites in
the prevalence of individual AREDs, low vision, and blind-
ness, the data were limited for several minority populations
(2,3). The estimates were based on three eye studies that
included African Americans; the prevalence of low vision
and blindness among Hispanics was estimated from one
study in southern Arizona (2,29). No information about
American Indians or Asian Americans exists. Finally, little
information is known about the way variable access to care
or other factors may contribute to the striking variations in
the prevalence of AREDs and loss of visual function.
Investigators in east Baltimore, Md, estimated that half of
the cases of blindness found in the community could have
been prevented or reversed with proper care (23).
AREDs are common and costly. Treatment for cataracts
accounted for 60% of the Medicare eye-care costs in the
1990s (30). In a longitudinal analysis of Medicare claims
for diabetic retinopathy, glaucoma, and macular degener-
ation, investigators documented that almost half of more
than 20,000 Medicare beneficiaries had developed at least
one of the three diseases in the 9-year follow-up period
(31). From the longitudinal data, the investigators con-
cluded that among people who live to age 65 years, the
probability of acquiring at least one of the three conditions
is 0.45. Decreased vision is associated with myriad prob-
lems in older adults, such as falls, hip fractures, family
stress, and depression (32). Vision disorders are also a
safety risk to all automobile drivers and passengers (33).
Reducing the level of disability caused by vision loss and
blindness is challenging for public health professionals for
many reasons. For example, the magnitude of the problem
is not completely understood because it is hard to measure
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vision loss and blindness accurately by the usual surveil-
lance methods (34). People with limited eyesight may be
less likely to have necessary examinations or answer sur-
veys commonly used to assess chronic conditions. State-
based blindness registries have not successfully docu-
mented the prevalence, risk factors, and trends in vision
loss (34). In addition, to prevent vision loss, conditions
such as glaucoma and diabetic retinopathy must be detect-
ed by careful and regular examinations before obvious
symptoms of vision loss develop. Comprehensive dilated-
eye examinations for these conditions are best performed
by eye-care specialists — optometrists and ophthalmolo-
gists. It is easy for the general public to assume, erro-
neously, that a test of visual acuity associated with obtain-
ing glasses or a driver’s license will detect sight-threaten-
ing conditions. In addition, the geographical distribution of
eye-care specialists is not known, and areas such as rural
and medically underserved communities may have short-
ages. Finally, medical services to detect and treat serious
eye diseases may not be integrated with the services need-
ed to improve quality of life and increase independence for
people with low vision. Glasses and other aids to improve
vision are not uniformly covered by health insurance.
Rehabilitation services to help people with vision loss are
administered by agencies experienced in helping individu-
als return to work but are not usually linked with public
health or home health services for older adults. Although
Healthy People 2010 (35) defines objectives for glaucoma,
cataracts, and diabetic retinopathy, few communities have
the resources to expand their efforts beyond diabetes-
related eye disease (36). The recent estimates provided by
The Eye Disease Prevalence Research Group not only
highlight the lack of sufficient information about the
prevalence of AREDs but also underscore the need for a
better understanding of access to eye-care and vision sup-
port services among various populations.
Conclusion
Public health professionals now have an additional
responsibility — to better describe and, more importantly,
address ARED and visual impairment prevalence dispari-
ties in the United States. The data provide a call to action.
To decrease morbidity from vision loss and blindness, pub-
lic health professionals must increase public awareness
about AREDs; integrate and coordinate timely screening,
diagnosis, and treatment to prevent or correct vision loss;
ensure continuity of care between medical treatment and
supportive care for vision loss from AREDs; and monitor
the status of visual impairment by using new methods for
identifying people affected and their extent of vision loss.
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